This article is more than 5 years old. Information may no longer be current.

Oculex completes phase 2 trial enrollment for macular edema implant

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

SUNNYVALE, Calif. — Oculex Pharmaceuticals Inc. has completed patient enrollment for its phase 2 clinical trial of the Posurdex drug delivery implant.

Posurdex is a biodegradable implant that delivers the corticosteroid dexamethasone to the posterior segment. The randomized, multicenter trial will evaluate the safety and efficacy of the implant for treating persistent macular edema. Potential improvements in visual acuity will also be evaluated.

More than 300 patients have been enrolled at more than 25 universities and ophthalmic centers in the United States. Oculex anticipates completion of the study by the middle of 2003.